February 2026
Microdosing
What February 2026's 9 new studies found, synthesized from the papers below. All Microdosing research →
The synthesis
Synthesized from 8 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Microdosing, micro-dosing, sub-perceptual dosing, low-dose psychedelics, then ranked by relevance.
Research on microdosing in February 2026 shows mixed results: a small Phase 2 RCT found no significant antidepressant effect of microdosed psilocybin over placebo, while a Phase 2a trial of LSD microdosing reported short-term mood improvements in depression. Epidemiological data indicate microdosing is common among young adults who use hallucinogens and is associated with higher rates of other substance use. The evidence is limited by small sample sizes, open-label phases, and a lack of consistent controlled findings.
Confidence in the evidence
Low-Moderate- Only one small RCT (n=39) on psilocybin microdosing for MDD showed null results, while a Phase 2a trial on LSD reported positive but preliminary findings.
- Epidemiological study (n=3094) provides prevalence data but no efficacy evidence.
- Qualitative meta-synthesis and scoping review highlight gaps in controlled research.
- No large, consistent, well-controlled trials confirm efficacy.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Epidemiology of Hallucinogen Microdosing Among Young Adults in the United States: A National Study 2026 | observational | 3094 | Unclear | Microdosing was reported by 6.8% of young adults and was associated with higher rates of other substance use. |
| Safety and Efficacy of Microdosing Psilocybin over 8 Weeks for Major Depressive Disorder: A Randomized Clinical Trial 2026 | RCT | 39 | No effect | Microdosed psilocybin (2 mg) did not outperform placebo in reducing depression symptoms after four weeks. |
| LSD microdosing for major depressive disorder: Mood and pharmacokinetic outcomes from a Phase 2a trial 2026 | Phase 2a trial | Supports | Short-term mood improvements were observed following microdosed LSD, with no tolerance or sensitization. | |
| Microdosing psilocybin for major depressive disorder: study protocol for a phase II double-blind placebo-controlled randomised partial crossover trial 2026 | study protocol | Unclear | This protocol describes a planned RCT to evaluate microdosing psilocybin for MDD, with results pending. | |
| Exploring a Decade of Microdosing Research: A Qualitative Meta-synthesis of Microdosing Literature 2026 | qualitative | Unclear | A meta-synthesis of 14 qualitative studies identified themes of self-enhancement and management of anxiety, depression, and stress. | |
| Self-medication with psychedelics: a scoping review and narrative synthesis of review-level evidence 2026 | scoping review | Unclear | Reviews on self-medication with psychedelics report psilocybin and LSD used primarily for cluster headache and chronic pain, with some benefits and harms. | |
| Bioactive compounds from Psilocybe cubensis mycelial cultures with transient anxiolytic effects in mice. 2026 | preclinical | Supports | Microdosing with P. cubensis mycelium showed transient anxiolytic effects in mice. | |
| Ayahuasca modulation of traumatic-like fear memories requires infralimbic cortex BDNF-dependent mechanisms in rats. 2026 | preclinical | Supports | Ayahuasca enhanced fear extinction and reduced fear generalization in rats, dependent on BDNF in the infralimbic cortex. |
Microdosing was reported by 6.8% of young adults and was associated with higher rates of other substance use.
observational Sample size: 3094
Microdosed psilocybin (2 mg) did not outperform placebo in reducing depression symptoms after four weeks.
RCT Sample size: 39
Short-term mood improvements were observed following microdosed LSD, with no tolerance or sensitization.
Phase 2a trial
This protocol describes a planned RCT to evaluate microdosing psilocybin for MDD, with results pending.
study protocol
A meta-synthesis of 14 qualitative studies identified themes of self-enhancement and management of anxiety, depression, and stress.
qualitative
Reviews on self-medication with psychedelics report psilocybin and LSD used primarily for cluster headache and chronic pain, with some benefits and harms.
scoping review
Microdosing with P. cubensis mycelium showed transient anxiolytic effects in mice.
preclinical
Ayahuasca enhanced fear extinction and reduced fear generalization in rats, dependent on BDNF in the infralimbic cortex.
preclinical
Points of agreement
- Microdosing is a growing practice, particularly among young adults and for mental health purposes.
- Preclinical studies suggest potential for anxiolytic and fear-extinction effects.
- Clinical trials on microdosing for depression show mixed results, with some positive signals but no robust evidence.
Conflicts
- The psilocybin RCT found no antidepressant effect over placebo, while the LSD trial reported short-term mood improvements.
- Epidemiological data show high rates of co-occurring substance use among microdosers, contrasting with anecdotal reports of health benefits.
Gaps
- Lack of large, well-controlled, long-term clinical trials on microdosing efficacy and safety.
- Durability of effects and optimal dosing regimens are not established.
- Limited data on diverse populations and potential harms, including substance use interactions.